[HTML][HTML] COVID-19 and the COVID-19 Vaccine in Japan—A Review from a General Physician's Perspective
H Kusunoki - Pharmacoepidemiology, 2023 - mdpi.com
More than 3 years have passed since the emergence of COVID-19. On 8 May 2023, COVID-
19 in Japan was downgraded to Category 5 by the Infectious Disease Control Law. In …
19 in Japan was downgraded to Category 5 by the Infectious Disease Control Law. In …
New‐onset and relapsed thrombotic microangiopathy post‐COVID‐19 vaccination
Q Ma, G Xu - Journal of Medical Virology, 2023 - Wiley Online Library
Thrombotic microangiopathy (TMA) associated with coronavirus disease 2019 (COVID‐19)
vaccination has been reported, however, the clinical characteristics and pathogenesis …
vaccination has been reported, however, the clinical characteristics and pathogenesis …
Molecular characteristics of circulating B cells and kidney cells at the single-cell level in special types of primary membranous nephropathy
X Feng, Q Chen, J Zhong, S Yu, Y Wang… - Clinical Kidney …, 2023 - academic.oup.com
Background Although primary membranous nephropathy (pMN) associated with podocyte
autoantibodies (POS) is becoming well-known, the molecular characteristics of the specific …
autoantibodies (POS) is becoming well-known, the molecular characteristics of the specific …
[HTML][HTML] Membranous nephropathy following full-dose of inactivated SARS-CoV-2 virus vaccination: a case report and literature review
T Thammathiwat, L Chompuk, S Worawichawong… - Vaccines, 2022 - mdpi.com
Vaccination against the SARS-CoV-2 virus (COVID-19) has proven to be the most effective
measure to prevent the spread and reduce infection severity. A case report of de novo …
measure to prevent the spread and reduce infection severity. A case report of de novo …
Combination of rituximab and short-term glucocorticoids in the treatment of anti-phospholipase A2 receptor antibody positive idiopathic membranous nephropathy
Q Ma, M Li, G Xu - Clinical and Experimental Medicine, 2023 - Springer
Rituximab (RTX) has been the first option in idiopathic membranous nephropathy (IMN).
However, the clinical effect was not very satisfactory. This study aimed to explore the clinical …
However, the clinical effect was not very satisfactory. This study aimed to explore the clinical …
[HTML][HTML] IgG4-Related Membranous Nephropathy After COVID-19 Vaccination: A Case Report
T Mizuno, Y Endo, A Suzuki, M Suzuki - Cureus, 2024 - ncbi.nlm.nih.gov
Abstract Although immunoglobulin G4 (IgG4)-related kidney diseases are typically
characterized by tubulointerstitial nephritis with abundant infiltration of IgG4-positive plasma …
characterized by tubulointerstitial nephritis with abundant infiltration of IgG4-positive plasma …
[PDF][PDF] Causal relationship between COVID-19 and membranous nephropathy: A bidirectional Mendelian randomization study
T Zhou, H Zhang, J Zhao, Y Ma, L He, Z Ren, F Lin… - 2024 - scholar.archive.org
Recent studies have suggested a potential link between COVID-19 and the initiation or
exacerbation of membranous nephropathy (MN) caused by the SARS-CoV-2 virus …
exacerbation of membranous nephropathy (MN) caused by the SARS-CoV-2 virus …
[PDF][PDF] Assessing the nature and rate of side effects to SARS-CoV-2 vaccines requires well-powered, prospective studies
J Finsterer - multiresearchjournal.com
We read with interest the article by Wang et al. about a cross-sectional study about adverse
reactions in vaccinees having received three doses of a vector-or RNA-based SARS-CoV-2 …
reactions in vaccinees having received three doses of a vector-or RNA-based SARS-CoV-2 …